The rs9939609 Polymorphism in the FTO Gene Is Associated with Fat and Fiber Intakes in Patients with Type 2 DiabetesSteemburgo T.a, b · Azevedo M.J.a · Gross J.L.a · Milagro F.I.b, c · Campión J.b, c · Martínez J.A.b, c
aEndocrine Division, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil; bDepartment of Nutrition and Food Sciences, Physiology and Toxicology, University of Navarra, Pamplona, and cCIBER Fisiopatología de la Obesidad y la Nutrición (CIBERobn), Madrid, Spain
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background/Aims: The common polymorphism in the FTO gene (rs9939609) has been associated with obesity, type 2 diabetes, and appetite regulation. The aim of this study was to evaluate possible associations of FTO rs9939609 with dietary factors in patients with type 2 diabetes. Methods: This was a cross-sectional study of 236 patients with type 2 diabetes (age 60.0 ± 10.3 years; diabetes duration 12.7 ± 8.2 years; 53.4% females) who were genotyped for FTO rs9939609. Patients underwent clinical and laboratory evaluations and 3-day weighed diet records. Data on dietary intake were categorized as high or low, based on median values. Results: The AA genotype in the FTO gene was positively associated with high fat (>34% energy; OR = 2.17; 95% CI 1.02-4.63) and low fiber intakes (<16 g/day; OR = 2.42; 95% CI 1.05-5.57), adjusted for gender, BMI, total energy intake, systolic blood pressure, and HbA1c. When gender was taken into account, AA females had higher fat (37.4 ± 5.3 vs. 32.6 ± 7.5 and 32.2 ± 6.2% energy; p = 0.005) and lower fiber intakes (12.4 ± 4.4 vs. 15.1 ± 6.3 and 16.7 ± 5.6 g/day; p = 0.023) than patients with TT and AT genotypes. Multiple logistic regression models confirmed female associations for high fat (OR = 9.73; 95% CI 2.12-44.66) and low fiber intakes (OR = 4.28; 95% CI 1.14-16.06; p < 0.05 for all models). Conclusions: Patients with type 2 diabetes, who were carriers of the AA genotype of the FTO rs9939609, had increased fat and decreased fiber consumption, independently of BMI.
© 2013 S. Karger AG, Basel
- Frayling TM, Timpson NJ, Weedon MN, et al: A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007;316:889-894.
- Dina C, Mey D, Gallin S, et al: Variation in FTO contributes to childhood obesity and severe adult obesity. Nat Genet 2007;39:724-726.
- Hunt SC, Stone S, Xin Y, et al: Association of the FTO gene with BMI. Obesity 2008;16:902-904.
- Chang YC, Liu PH, Lee WJ, et al: Common variations in the FTO gene confers risk of obesity and modulates body mass index in the Chinese population. Diabetes 2008;57:2245-2252.
- Hota K, Nakata Y, Matsuo T, et al: Variations in the FTO gene are associated with severe obesity in the Japanese. J Hum Genet 2008;53:546-553.
- Day FR, Loos RJ: Developments in obesity genetics in the era of genome-wide association studies. J Nutrigenet Nutrigenomics 2011;4:222-238.
- Yajnik CS, Janipalli CS, Bhaskar S, et al: FTO gene variants are strongly associated with type 2 diabetes in South Asian Indians. Diabetologia 2009;52:247-252.
- Li H, Kilpeläinen TO, Liu C, et al: Association of genetic variation in FTO with risk of obesity and type 2 diabetes with data from 96,551 East and South Asians. Diabetologia 2012;55:981-995.
- Jacobsson JA, Danielsson P, Svensson V, et al: Major gender difference in association of FTO gene variant among severely obese children with obesity and obesity related phenotypes. Biochem Biophys Res Commun 2008;368:476-482.
- Lappalainen TJ, Tolppanen AM, Kolehmainen M, et al: The common variant in the FTO gene did not modify the effect of lifestyle changes on body weight: the Finnish Diabetes Prevention Study. Obesity 2009;17:832-836.
- Al-Attar S, Pollex RL, Ban MR, et al: Association between the FTO rs9939609 polymorphism and the metabolic syndrome in a non-Caucasian multi-ethnic sample. Cardiovasc Diabetol 2008;7:1-6.
- Zhou D, Liu H, Zhou M, et al: Common variant (rs9939609) in the FTO gene is associated with metabolic syndrome. Mol Biol Rep 2012;39:6555-6561.
- Costa LA, Canani LH, Lisbo HRK, et al: Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in type 2 diabetes. Diabet Med 2003;21:252-255.
- Hertel JK, Johansoon S, Raeder H, et al: Genetic analysis of recently identified type 2 diabetes loci in 1,638 unselected patients with type 2 diabetes and 1,858 control participants from a Norwegian population-based cohort (the Hunt study). Diabetologia 2008;51:971-977.
- Timpson NJ, Emmett PM, Frayling TM, et al: The fat mass- and obesity-associated and dietary intake in children. Am J Clin Nutr 2008;88:971-978.
- Sonestedt E, Roos C, Gullberg B, et al: Fat and carbohydrate intake modify the association between genetic variation in the FTO genotype and obesity. Am J Clin Nutr 2009;90:1418-1425.
- Wardle J, Llewellyn C, Sanderson S, et al: The FTO gene and measured food intake in children. Int J Obes 2009;33:42-45.
- Speakman JR, Rance KA, Johnstone AM: Polymorphisms of the FTO gene are associated with variation in energy intake, but not energy expenditure. Obesity 2008;16:1691-1695.
- Cecil JE, Tavendale R, Watt P, et al.: An obesity-associated FTO gene variant and increased energy intake in children. N Engl J Med 2008;359:2558-2566.
- Berentzen T, Kring SI, Holst C, et al: Lack of association of fatness-related FTO gene variants with energy expenditure or physical activity. J Clin Endocrinol Metab 2008;93:2904-2908.
- Wardle J, Carnell S, Haworth CM, et al: Obesity associated genetic variation in FTO is associated with diminished satiety. J Clin Endocrinol Metab 2008;93:3640-3643.
- Hoed MD, Westerterp-Plantenga MS, Bouwman FG, et al: Postprandial responses in hunger and satiety are associated with the rs9939609 single nucleotide polymorphism in FTO. Am J Clin Nutr 2009;90:1426-1432.
- Tuomilehto L, Lindstron J, Eriksson JG, et al: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;334:1343-1350.
- Chobanian AV, Bakris GL, Black HR, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2572.
- Alberti KG, Eckel RH, Grundy SM, et al: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-1645.
- Gross JL, Azevedo MJ, Silveiro SP, et al: Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005;28:164-176.
- Moulin CC, Tiskievicz F, Zelmanovitz T, et al: Use of weighed diet records in the evaluation of diets with different protein contents in patients with type 2 diabetes. Am J Clin Nutr 1998;67:853-857.
- Vaz JS, Bittencourt M, Almeida JC, et al: Protein intake estimated by weighed diet records in patients with type 2 diabetes: misreporting and intra-individual variability using 24-hour nitrogen output as criterion standard. J Am Diet Assoc 2008;108:867-872.
- Goldberg GR, Black AE, Jebb SA, et al: Critical evaluation of energy intake data using fundamental principles of energy physiology: 1. Derivation of cut-off limits to identify under-recording. Eur J Clin Nutr 1991;45:569-581.
USDA SR 13 Research Quality Nutrient Data, The Agricultural Research Service: Composition of foods. Agricultural Handbook No. 8. Washington, US Department of Agriculture, 1998.
WHO: Energy and protein requirements: report of a joint FAO/WHO/UNU Expert Consultation. Geneva, World Health Organization, 1985.
- Jacobsson JA, Klovins J, Kapa I, et al: Novel genetic in FTO influences insulin levels and insulin resistance in severely obese children and adolescents. Int J Obes 2008;32:1730-1735.
- Grau K, Hansen T, Holst C, et al: Macronutrient-specific effect of FTO rs9939609 in response to a 10-week randomized hypo-energetic diet among obese Europeans. Int J Obes 2009;33:1227-1234.
- Stratigopoulos G, Padilha SL, LeDuc CA, et al: Regulation of Fto/Ftm gene expression in mice and humans. Am J Physiol Regul Integr Comp Physiol 2008;294:R1185-R1196.
- Loos RJ, Bouchard C: FTO: the first gene contributing to common forms of human obesity. Obes Rev 2008;9:246-250.
- Steemburgo T, Dall'Alba V, Almeida JC, et al: Intake of soluble fibers has a protective role for the presence of metabolic syndrome in patients with type 2 diabetes. Eur J Clin Nutr 2009;63:127-133.
- Black AE: Critical evaluation of energy intake using the Goldberg cut-off for energy intake: basal metabolic rate. A practical guide to its calculation, use and limitations. Int J Obes Relat Metab Disord 2000;24:1119-1130.
- Afman L, Muller M: Nutrigenomics: from molecular nutrition to prevention of disease. J Am Diet Assoc 2009;106:569-576.
- Marti A, Martinez-González MA, Martinez JA: Interaction between genes and lifestyle factor on obesity. Proc Nutr Soc 2008;67:1-8.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.